The Group's principal activities are manufacturing and marketing health care products. The Group operates through two segments namely: Diabetes Care and Bio pharmaceuticals. Diabetes care segment includes discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products (OAD). Biopharmaceuticals segment includes discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management (NovoSeven), growth hormone therapy, hormone replacement therapy and other products. The Group operates globally.
Alacra Alerts:
Receive alerts on the latest reports on Novo-Nordisk A/S
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
